RNA vs OABI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 22, 2026

RNA

37.1
AI Score
VS
RNA Wins

OABI

36.8
AI Score

Investment Advisor Scores

RNA

37score
Recommendation
SELL

OABI

37score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNA OABI Winner
Revenue 22.64M 27.84M OABI
Net Income -36.82M -13.57M OABI
Net Margin -162.6% -48.7% OABI
Operating Income -39.90M -14.47M OABI
ROE -17.2% -5.2% OABI
ROA -13.1% -4.7% OABI
Total Assets 280.51M 290.26M OABI
Cash 72.33M 24.34M RNA
Current Ratio 8.73 4.80 RNA
Free Cash Flow -37.20M -2.51M OABI

Relative Price Performance (Last 90 Days)

RNA 1M: +10.8% · 3M: +1.2% OABI 1M: +112.3% · 3M: +69.8%

Current Technical Phase

RNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 61

RSI (14): 60.7 · Price: $13.20

OABI

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.1% over 20 days), RSI 89

RSI (14): 89.3 · Price: $4.33

Fundamentals Snapshot

Metric RNA OABI
Market Cap
Forward P/E -2.1 -14.7
Trailing P/E
Revenue (TTM)
Revenue Growth 11.5% 2.4%
Gross Margin -0.3% 1.0%
Operating Margin -0.9% -0.5%
EPS -4.98 -0.36
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.